What Integra LifeSciences (IART) Investors Need to Know Today

Shares of Health Care sector company Integra LifeSciences moved -4.6% today, and are now trading at a price of $35.5. The mid-cap stock's daily volume was 219,788 compared to its average volume of 647,596. The S&P 500 index returned a -1.0% performance.

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. The company is based in Princeton and has 3,722 full time employees. Its market capitalization is $2,889,835,008.

9 analysts are following Integra LifeSciences and have set target prices ranging from $36.0 to $60.0 per share. On average, they have given the company a rating of hold. At today's prices, IART is trading -24.29% away from its average analyst target price of $46.89 per share.

Over the last year, IART shares have gone down by -25.0%, which represents a difference of -36.0% when compared to the S&P 500. The stock's 52 week high is $60.69 per share and its 52 week low is $33.44. With average free cash flows of $181.76 Million that have been growing at an average rate of 4.1% over the last 6 years, Integra LifeSciences declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 208,082 52,863 155,219 -30.12
2022 264,469 42,343 222,126 -15.99
2021 312,427 48,022 264,405 60.3
2020 203,832 38,890 164,942 1.88
2019 231,433 69,537 161,896 32.76
2018 199,683 77,741 121,942
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.